Effect of pepleomycin in prostatic cancer. A preliminary report
- PMID: 6163206
Item in Clipboard
Effect of pepleomycin in prostatic cancer. A preliminary report
Scand J Urol Nephrol Suppl.
1980.
Abstract
Six patients with prostatic carcinoma entered this clinical trial using Pepleomycin, an analogue of Bleomycin, administered intramuscularly in a total dose of 120 mg. Two patients had an objective improvement lasting for three months. Also subjective improvement was observed in one patient. The main side effects were gastrointestinal disturbances, dermatologic symptoms and fever. However, pulmonary fibrosis, a well-known complication of Bleomycin therapy, could not be found.
Similar articles
-
Chemotherapy of advanced prostatic cancer with peplomycin.Prostate Suppl. 1981;1:103-10. doi: 10.1002/pros.2990020517. Prostate Suppl. 1981. PMID: 6176978
-
A review of clinical studies of pepleomycin.Recent Results Cancer Res. 1980;74:163-71. doi: 10.1007/978-3-642-81488-4_21. Recent Results Cancer Res. 1980. PMID: 6160600 Review.
-
Pulmonary toxicity induced by pepleomycin 3-[(S)-1'-phenylethylamino] propylamino-bleomycin.Jpn J Clin Oncol. 1983 Jun;13(2):395-410. Jpn J Clin Oncol. 1983. PMID: 6193296
-
[Clinical experiences with pepleomycin].Gan To Kagaku Ryoho. 1982 May;9(5):930-5. Gan To Kagaku Ryoho. 1982. PMID: 6191706 Japanese.
-
Bleomycin and the skin.Br J Dermatol. 2006 Nov;155(5):869-75. doi: 10.1111/j.1365-2133.2006.07474.x. Br J Dermatol. 2006. PMID: 17034512 Review.
MeSH terms
Substances
LinkOut - more resources
Medical